United Therapeutics Corporation ($UTHR) Stock Forecast: Up 5.1% Today

What is United Therapeutics Corporation?

United Therapeutics (UTHR) is a biotechnology company focusing on developing and commercializing innovative products for patients with chronic and life-threatening conditions. The market sentiment regarding the company has been mixed due to varying analyst expectations and financial performance.

Why is United Therapeutics Corporation going up?

UTHR stock is up 5.1% on Aug 1, 2025 16:06

• The reasons for the bullish movement in UTHR stock are:
• Strong Tyvaso sales contributing to a 12% increase in revenues year-over-year.
• Despite missing earnings estimates for the second quarter, the market reacted positively to the company's revenue growth.
• The announcement of a share repurchase program of up to $1 billion by the company's board may have instilled confidence in investors concerning future prospects.
• Investors seem to be concentrating more on the revenue growth and potential of the company's product portfolio rather than short-term earnings misses.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y

United Therapeutics' second-quarter earnings miss estimates, while revenues rise 12% on strong Tyvaso and other product sales.

https://www.zacks.com/stock/news/2644115/uthr-q2-earnings-miss-estimates-higher-tyvaso-sales-aid-revenues-yy

United Therapeutics Stock Slides On Q2 Earnings: The Details - United Therapeutics ( NASDAQ:UTHR )

United Therapeutics misses analyst estimates on the top and bottom lines in the second quarter. The company's board authorizes a share repurchase program of up to $1 billion. The market's back, and these 3 income stocks are thriving. See them here→

https://www.benzinga.com/trading-ideas/movers/25/07/46728830/united-therapeutics-stock-slides-on-q2-earnings-the-details

United Therapeutics ( UTHR ) Misses Q2 Earnings Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -5.74% and +0.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2637884/united-therapeutics-uthr-misses-q2-earnings-estimates

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.2% Today

XRP ($XRP) Crypto Forecast: Down 5.1% Today

Cardano ($ADA) Crypto Forecast: Down 5.1% Today

Chainlink ($LINK) Crypto Forecast: Down 5.4% Today

Lithia Motors Inc. ($LAD) Stock Forecast: Up 5.1% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.0% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Down 12.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 6.7% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 7.2% Today

Pfizer Inc. ($PFE) Stock Forecast: Up 5.0% Today

United Therapeutics Corporation Price History

28.07.2024 - UTHR Stock was up 5.0%

• The price target for UTHR was raised from $400 to $575, suggesting optimism and growth potential.
• The CEO selling over $2.5 million in company stock may be interpreted as profit-taking, but investors remained confident in the company's performance.
• The upbeat forecast for UTHR, along with the higher price target from analysts, probably influenced the market's bullish trend today.

28.07.2024 - UTHR Stock was up 5.3%

• The positive market sentiment surrounding UTHR's product pipeline and potential for addressing medical needs likely drove the bullish movement in the stock.
• The recent sale of over $2.5 million in UTHR stock by the company's CEO may have sparked initial investor concerns, but it was likely viewed as a strategic decision rather than a reflection of UTHR's performance.
• The overall upbeat outlook in the biotechnology industry, as seen in a recent industry comparison, may have also influenced investors and contributed to UTHR's stock's bullish movement today.

26.01.2025 - UTHR Stock was down 8.1%

• Despite United Therapeutics surpassing Q4 earnings and revenue estimates, the stock experienced a bearish movement, indicating that the market may have had higher expectations.
• Investors might have been disappointed with the company's future guidance or outlook, leading to a sell-off of the stock.
• The market may have reacted negatively to key metrics that fell short of Wall Street projections, causing a decline in UTHR's stock price.

16.09.2024 - UTHR Stock was up 2.5%

• UTHR has shown remarkable performance in the market, boasting an impressive average annual return of 33.66% over the past 5 years.
• The stock's significant bullish movement today may be attributed to its continuous growth and the favorable market sentiment towards its innovative therapies.
• Investors are showing confidence in United Therapeutics' market position and growth potential, evident in its current market capitalization of $15.89 billion.

09.03.2025 - UTHR Stock was down 5.7%

• Despite the positive market sentiment and expectations of a strong performance in the upcoming period, UTHR faced significant bearish movement today.
• This unexpected downturn may be linked to investors taking profits, potentially motivated by the anticipation of positive earnings.
• Market dynamics or external factors could have also played a role in the stock's decline, counter to the optimistic outlook for UTHR's future earnings.

07.04.2025 - UTHR Stock was up 5.2%

• A dispute filed by United Therapeutics against Liquidia was dismissed by the District Court.
• UTHR's Q1 earnings and revenues exceeded estimates, driven by increased Tyvaso sales.
• The favorable legal outcome and strong financial results are believed to have influenced the bullish movement in UTHR's stock price today.

01.07.2025 - UTHR Stock was up 5.1%

• The reasons for the bullish movement in UTHR stock are:
• Strong Tyvaso sales contributing to a 12% increase in revenues year-over-year.
• Despite missing earnings estimates for the second quarter, the market reacted positively to the company's revenue growth.
• The announcement of a share repurchase program of up to $1 billion by the company's board may have instilled confidence in investors concerning future prospects.
• Investors seem to be concentrating more on the revenue growth and potential of the company's product portfolio rather than short-term earnings misses.

12.01.2025 - UTHR Stock was up 1.2%

• The positive movement in UTHR today could stem from favorable market sentiment towards the company's recent product advancements or financial performance.
• Comparisons made between UTHR and ZTS may have played a role in boosting investor trust in UTHR, potentially positioning UTHR as an appealing investment choice.
• Investors may have viewed UTHR as a more attractive stock in terms of value compared to ZTS, leading to increased buying interest and driving up the stock price.
• In summary, today's uptick in UTHR may be a result of internal company factors as well as evaluations against industry peers in the biotechnology field.

30.06.2025 - UTHR Stock was down 5.4%

• UTHR reported Q2 earnings that missed analyst estimates on both the top and bottom lines, leading to a bearish movement in the stock.
• The company's announcement of a share repurchase program of up to $1 billion did not seem to offset the disappointment from the earnings miss.
• The stock crossing above the 50-day moving average could have initially signaled a positive trend, but the earnings results likely overshadowed this technical indicator, causing the bearish movement.
• Investors may be concerned about the company's future performance based on the Q2 results, leading to a sell-off in the stock.

10.05.2025 - UTHR Stock was down 10.7%

• UTHR's bearish movement could be attributed to profit-taking by investors after a period of growth or due to concerns about the company's future performance.
• The potential struggles of Corcept (CORT) after their last earnings report may have had a spillover effect on UTHR, causing investors to be cautious about the biotechnology sector as a whole.
• Investors might be reevaluating their positions in biotech stocks, leading to a broader sell-off in the sector and impacting UTHR negatively.
• It is essential for investors to closely monitor both company-specific news and industry trends to make informed decisions in the volatile biotechnology market.

30.06.2025 - UTHR Stock was down 4.2%

• UTHR stock witnessed a significant decline in value today.
• Falling short of Q2 earnings estimates by -5.74% potentially influenced the downward trajectory.
• Although surpassing the 50-day moving average, investors' response to the earnings disappointment likely drove the negative trend.
• Investor sentiment concerning UTHR may be influenced by apprehensions regarding future performance following the recent earnings outcome.

30.03.2025 - UTHR Stock was up 2.1%

• UTHR's strong bullish movement today can be attributed to the company's impressive Q1 earnings and revenue results, surpassing analyst estimates by 5.41% and 9.39% respectively. This positive financial performance likely instilled confidence in investors, driving up the stock price.
• Despite the overall bullish market movement, it's interesting to note that there were downgrades from a top analyst, which could have initially caused some uncertainty. However, the market seemed to focus more on the robust earnings report, overshadowing the analyst's revised outlook.
• The market's reaction indicates that investors placed more weight on UTHR's solid financial fundamentals rather than the analyst's downgrade, showcasing the significance of strong earnings in influencing stock price movements.